Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Govt’s Modified PMP Plan: “1-Year Cutoff” Extended for 3 Years, 25% of Firms Could Now Maintain Full Prices
December 8, 2017
- Easing of Proposed PMP Requirements Likely, Major Focus on “One-Year Cutoff” and “Category I” Scope
December 7, 2017
- (Update) NHI-Market Drug Price Gap at 9.1%, 7.1% Regular Price Cut Expected in FY2018
December 6, 2017
- ICH Completes Guidelines for Multiregional Clinical Trials; Could Accelerate Simultaneous Global Development
December 6, 2017
- MHLW Reviewing PMP in View of People’s Understanding: Health Insurance Chief
December 6, 2017
- Checklist Presented for Excluding Foundation-Funded Programs from “Specified Clinical Research”
December 6, 2017
- NHI-Market Drug Price Gap at 9.1%, 7.1% Regular Price Cut Expected in FY2018
December 6, 2017
- MHLW Advisory Panel Backs Otsuka’s Schizophrenia Med Brexpiprazole and More
December 5, 2017
- Novo’s Semaglutide Stumbles as Panel Puts a Hold on Japan Approval
December 5, 2017
- Opdivo Earns Orphan Status for Malignant Pleural Mesothelioma
December 4, 2017
- MHLW Floats Incentives to Stem Antibiotic Overuse, but Payer Reps Negative: Chuikyo
December 4, 2017
- MHLW Presents Example of COI Management Guidelines for “Specified Clinical Research”
December 4, 2017
- CEFP Members Want Quicker Cuts for Off-Patent Drugs, Pricing Debate Enters Final Stretch
December 4, 2017
- Keytruda Earns Lymphoma Nod, Novo’s Norditropin Label Expanded
December 1, 2017
- LDP Lawmakers Lash Out at Govt's Drug Pricing Proposals
December 1, 2017
- Full-Scale CEA Rollout to Be Delayed into FY2019: Official
December 1, 2017
- MHLW Looks to Lift Ban on Exports of Plasma Fraction Products by FY2020
December 1, 2017
- Abolish PMP or Narrow Down Its Scope: MOF Panel FY2018 Budget Recommendation
November 30, 2017
- Off-Year Revisions Should Be Confined to Limited Scope, JPWA Says at Chuikyo
November 30, 2017
- Regulators Will Be Involved in Safety Data Transition for LLP Withdrawals: MHLW Official
November 30, 2017
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…